Evidence map›Paper›PMID 42618714›Full record

ArticleAdvances in therapy2026

BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.

Rahul Banerjee, Hamza Hashmi, Preet M Chaudhary, Shebli Atrash, Kimberly Green, Sabyasachi Ghosh, Todd Bixby, Denise De Wiest, Matthew Perciavalle, David H Vesole and 12 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Rahul BanerjeeFred Hutchinson Cancer Center, Seattle, WA, USA. rahul.banerjee.md@gmail.com.ORCID http://orcid.org/0000-0003-3781-5441
Hamza HashmiDavid H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Preet M ChaudharyKeck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Shebli AtrashLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Kimberly GreenDivision of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA.
Sabyasachi GhoshJohnson & Johnson, Horsham, PA, USA.
Todd BixbyJohnson & Johnson, Horsham, PA, USA.
Denise De WiestJohnson & Johnson, Horsham, PA, USA.
Matthew PerciavalleLegend Biotech USA Inc, Somerset, NJ, USA.
David H VesoleJohn Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.
Forat LutfiHematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, USA.
Waqas JehangirHematology, Transplant & Cellular Therapy, Avera Medical Group, Sioux Falls, SD, USA.
Gurbakhash KaurTisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
Adeel M KhanSimmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Rahma WarsameMayo Clinic College of Medicine and Science, Rochester, MN, USA.
Ashwathi Puravankara MenonRTI Health Solutions, Barcelona, Catalonia, Spain.
Mark A PriceRTI Health Solutions, Cascais, Portugal.
Guru Subramanian Guru MurthyDivision of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Danai DimaFred Hutchinson Cancer Center, Seattle, WA, USA.
Brian J CarneyDivision of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Zaina P QureshiJohnson & Johnson, Horsham, PA, USA.
Saurabh ChhabraDepartment of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic College of Medicine and Science, Phoenix, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe aimed to achieve consensus on optimal bridging therapy (BT) selection for patients with relapsed/refractory multiple myeloma (RRMM) undergoing chimeric antigen receptor T-cell (CAR-T) therapy.

methodsWe conducted a double-blind, three-round modified Delphi panel among U.S.-based hematologist-oncologists/hematologists using CAR-T therapy for RRMM.

resultsPanelists (N = 15; all managing -60-100 patients with RRMM within the past year; > 5 years of practice: 86.7%) reached consensus on key attributes influencing BT selection (disease burden, aggressive disease, performance status, comorbidities, line of therapy, age, frailty). Unique patient attributes were linked to clinical objectives (≥ 65 years or frailty: disease stabilization [71% consensus]; poor performance status: end-organ function preservation; comorbidities: functional preservation; high disease burden: preventing clinical decline; aggressive disease: cytoreduction [all 100% consensus]). Goals of BT were to decrease disease burden and promote CAR-T efficacy and safety (100% consensus). While talquetamab was preferred for bridging in later lines (66.7%), 73.3% would consider earlier-line use if approved.

conclusionThis study synthesized expert physician perspectives to develop a consensus-based framework to optimize BT selection, linking five key patient attributes to clinical objectives, with goals extending beyond disease stabilization to enhancing CAR-T efficacy and safety. Graphical abstract available for this article 10.6084/m9.figshare.33016328.

Indexed as

Bridging therapyCAR T-cell therapyCiltacabtagene autoleucelIdecabtagene vicleucelMultiple myelomaTalquetamab

Identifiers

PMID42618714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.